You are here: Industry Insights > NASH

News List

Gilead announces Novo Nordisk NASH partnership after new data revealed pharmatimes
April 16, 2019
Gilead Sciences has announced its intent to initiate a clinical collaboration with Novo Nordisk for a trial ……
Intercept reports additional positive data for Ocaliva in late-stage NASH trial firstwordpharma
April 12, 2019
Intercept reports additional positive data for Ocaliva in late-stage NASH trial.
Intercept sputters as it reveals full Ocaliva NASH data to doctors biopharmadive
April 12, 2019
Intercept is in the enviable position of leading in a heated competition to get the first NASH treatment to the market.
Phase 3 STELLAR-4 Study of Selonsertib Did Not Meet Primary Endpoint americanpharmaceuticalreview
February 13, 2019
Gilead Sciences announced STELLAR-4, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once-daily, oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1).....
Second Genome Doses First Patient in SGM-1019 Study americanpharmaceuticalreview
January 24, 2019
Second Genome announced the first patient has been dosed in a Phase 2 clinical trial evaluating SGM-1019 for the treatment of nonalcoholic steatohepatitis (NASH). SGM-1019 is a first-in-class....
Merck gains NASH candidate from NGM Biopharmaceuticals pharmaceutical-technology
January 08, 2019
Merck has exercised the option to license an investigational product called NGM313 from NGM Biopharmaceuticals under a strategic agreement signed between the companies in 2015.....
Gilead Sciences, Yuhan to treat advanced fibrosis due to NASH biospectrumasia
January 07, 2019
Gilead Sciences, Inc. and Yuhan Corporation has announced that the companies have entered into a licensing and collaboration agreement to co-develop novel therapeutic candidates for the treatment of patients....
NASH market forecast to be worth $18.3bn by 2026 pharmaceutical-technology
January 03, 2019
Due to increasing rates of obesity and diabetes, non-alcoholic steatohepatitis (NASH), a chronic inflammatory liver disease, is becoming increasingly prevalent.
Promethera looks to Asia with €10m investment pharmaphorum
January 03, 2019
Belgium-based liver disease specialists Promethera Biosciences have received a leg-up for the Asian market in the form of a €10 million investment from Japanese business conglomerate ITOCHU Corporation.
NASH-focused Akero Therapeutics adds another $70M to the bank fiercebiotech
December 26, 2018
Just six months after bagging a $65 million series A, Akero Therapeutics is at it again. The company has?reeled in?$70 million in its B round that will push its lead asset.....